Balancing Speed and Evidence in Developing COVID-19 Therapies

• Keynote Speaker: Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center: Balancing speed and evidence in COVID-19 trials
• Thomas Jaki, PhD, Co-investigator of the UK-RECOVERY trial, Professor, Department of Mathematics & Statistics, Lancaster University: Designing efficient clinical trials during a pandemic: Some personal lessons from the RECOVERY trial
  Julia Niewczas, PhD, Principal Clinical Trial Design Methodology Expert, AstraZeneca, Statistical challenges of designing COVID-19 therapeutic and prophylaxis trials
• Hemal B. Mehta, PhD, Assistant Professor, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health: Balancing speed and evidence in COVID-19 trials
• Natalia (Natasha) Mühlemann, MD, MBA, Vice President, Strategic Consulting, Cytel: A Bayesian design for COVID-19 trials with focus on vaccine development
• Rajat Mukherjee, PhD, Research Fellow, Strategic Consulting, Cytel: A Bayesian design for COVID-19 trials with focus on vaccine development

The Bay area Biotech-pharma Statistical Workshop (BBSW) is a collaborative initiative supported by companies, academic institutions, and nonprofit organizations in the San Francisco Bay Area. Its mission is to promote connection, leadership, growth and impact of the SF Bay Area statistics and quantitative science community.

More information about the BBSW can be found here.